"Outstanding" ADC Candidates Emerge for SCLC, Other Cancers - PubMed
4 hours ago
- #small cell lung cancer
- #clinical trials
- #antibody-drug conjugate
- New antibody-drug conjugates (ADCs) show promise for treating small cell lung cancer (SCLC).
- Early phase I data highlight robust response rates for CD56-targeting DXC006, DLL-3-targeting BL-M14D1, and B7-H3-targeting SYS6043.
- SYS6043 is also active in ovarian and breast cancers, while trastuzumab brengitecan shows strong efficacy in platinum-resistant ovarian cancer in phase II.